ATG - Access To Genome

What ATG - Access To Genome does

ATG - Access To Genome operates a regional network of eight medical genetics and specialized diagnostic laboratories headquartered in Greece with operations extending to Belgrade, Serbia. The company offers a comprehensive clinical genetics menu spanning non-invasive prenatal testing (Panorama NIPT, distributed in partnership with Natera), karyotyping via its proprietary Complete Cytoview 512 system, aCGH and MLPA-based copy number analysis, NGS gene panels, exome sequencing, hereditary cancer testing, and reproductive genetics. Diagnostic operations run on validated Roche platforms (Cobas z 480 for molecular workflows, Elecsys for immunoassays), with variant interpretation supported by Varsome Clinical under ACMG guidelines. The company is staffed by 57 employees, including EBMG-certified clinical geneticists, and is led by founders Ioannis Papoulidis, Emmanouil Manolakos, and Yolanda Gyftodimou, supported by a peer-reviewed publication record exceeding 89 papers.

The business model is a fee-for-service clinical laboratory operation: revenue is generated per test ordered, with demand sourced primarily through physician referrals (obstetricians, gynecologists, oncologists, clinical geneticists) and direct patient requests. Pricing is set against Greek private-pay and EOPYY reimbursement schedules, with international revenue accessed via the Belgrade site. ATG monetizes across multiple modalities — prenatal screening, cytogenetics, molecular oncology, rare disease exome analysis, infectious disease (COVID-19 molecular testing), and biopathology services under the acquired Biopathologiki sub-brand — which diversifies per-test revenue mix. Quality and competitive positioning are reinforced by an unusually dense accreditation stack: ISO 9001:2015, ISO 15189, ESYD accreditation, INSTAND EQAS participation, WHO standards compliance, and GenQA proficiency, which together function as gating credentials for institutional referral contracts in the region.

The company pursues a regional roll-up strategy, expanding menu breadth (NIPT, exome, COVID-19, biopathology, mammography, ultrasound) while extending physical reach within Greece and across the Balkans. Strategic positioning emphasizes full-stack genetic diagnostics under one roof — from cytogenetics to advanced genomics — rather than narrow specialization, supported by partnerships with global assay providers (Natera, Roche) and clinical bioinformatics tooling (Varsome). Growth is self-funded, with no disclosed external financing rounds, implying capital allocation is constrained to operating cash flow.

Name

ATG - Access To Genome

Legal name

ATG - Access To Genome

Website

https://atg-labs.gr

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

ATG - Access To Genome operates a regional network of eight medical genetics and specialized diagnostic laboratories across Greece and Serbia, offering NIPT, cytogenetics, exome sequencing, hereditary cancer testing, and biopathology services to physician-referred patients.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Clinical diagnostics
• Genetic testing
• Molecular diagnostics
• Cytogenetics services
• Laboratory network

Headquarters

HQ city

Thessaloniki (Kalamaria)

HQ country

Greece

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Laboratory Services: ATG generates revenue through fees for specialized diagnostic laboratory services including genetic testing (prenatal, preimplantation, hereditary cancer, infertility), molecular biology tests, biopathology analyses (hematological, biochemical, immunological, hormonological, coagulation, microbiological), cytology, DEXA imaging, and COVID-19 testing. Services are provided directly at diagnostic center locations to referred patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ATG - Access To Genome operates a clinical diagnostics laboratory network offering genetic, molecular biology, biopathology, and cytology diagnostic services. The company serves both individual patients through referrals and institutional clients including hospitals, clinics, and healthcare providers across Greece and Serbia. It provides advanced molecular and cytogenetic analyses including prenatal screening, postnatal diagnostics, hereditary disease panels, and hematology/oncology testing.

Product overview

ATG - Access To Genome is a network of medical genetics and specialized diagnostic laboratories operating in Thessaloniki, Athens, and Belgrade (Serbia) since 2006. The company offers a comprehensive portfolio of genetic and diagnostic testing services organized into five core departments: Molecular Genetics, Cytogenetics, Clinical Genetics & Genetic Counseling, Biopathology, and Cytology. The primary service offerings include Non-Invasive Prenatal Testing (NIPT) using Panorama technology from Natera, Preimplantation Genetic Screening and Diagnosis (PGS/PGD) using NGS and aCGH technologies, Prenatal Genetic Testing with molecular karyotype including Complete Cytoview 512, Genetic Diseases and Syndromes Testing via NGS gene panels, Genetic Testing for Hereditary Cancer, and fertility/miscarriage genetic investigation. Additional diagnostic services include SARS-CoV-2 molecular and antibody testing, DEXA bone density measurement, cytology (Pap tests), and specialized biopathology testing. The laboratory operates advanced technologies including Next Generation Sequencing (NGS), array CGH (aCGH), QF-PCR, FISH analysis, conventional karyotyping, and utilizes Varsome Clinical bioinformatics platform for exome sequencing variant interpretation.

Differentiator

Problem solved

Functional benefit

Brands

• Biopathologiki: Biopathology laboratory brand operating under ATG network, website at biopathologiki.gr

Products and services

• Prenatal Genetic Screening

Quantifiable outcome

• >98% sensitivity for NIPT detection of common genetic syndromes
• +5 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Natera S.A.coreTechnology or IntegrationNatera S.A. (California, USA) provides the Panorama Non-Invasive Prenatal Test technology to ATG. ATG offers Panorama testing which uses single nucleotide polymorphism (SNP) technology for prenatal screening of chromosomal abnormalities including trisomies 21, 18, 13, sex chromosome abnormalities, and microdeletion syndromes. The test has >98% sensitivity and is CE-IVD and CLIA certified.
• Roche DiagnosticscoreTechnology or IntegrationRoche Diagnostics provides the Cobas z 480 system used at ATG for SARS-CoV-2 molecular detection via real-time PCR. The system is a certified IVD (In Vitro Diagnostic) platform enabling high specificity and sensitivity detection of coronavirus RNA through two target genes.
• Roche Diagnostics (Elecsys)coreTechnology or IntegrationRoche's Elecsys Anti-SARS-CoV-2 system is used at ATG for qualitative detection of total IGG and IGM antibodies against SARS-CoV-2, with sensitivity up to 100% (95% CI 88.1-100) at 14 days post positive PCR and 99.8% specificity.
• INSTAND e.V.minorOthersINSTAND is a German external quality assessment provider. ATG participates in INSTAND EQAS proficiency testing schemes, which are international external quality control programs for clinical laboratories ensuring diagnostic accuracy and reliability.
• Genomics Quality Assessment (GenQA)minorOthersGenQA is a UK-based genomics quality assessment organization. ATG participates in GenQA external quality control schemes specific to genetic and genomic testing, demonstrating proficiency in molecular genetics testing standards.
• European Board of Medical Genetics (EBMG)minorOthersThe European Board of Medical Genetics awards the Clinical Laboratory Geneticist specialty title. ATG's directors Ioannis Papoulidis and Emmanouil Manolakos hold EBMG specialty certifications, demonstrating adherence to European professional standards in medical genetics.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• LabGenetics: LabGenetics is a Spanish molecular genetics laboratory providing NIPT, prenatal diagnosis, hereditary cancer testing, and pharmacogenetics. It is a direct peer to ATG with a similar specialty genetics focus, NGS workflows, and Mediterranean-market physician referral model.
• Eurofins Genoma Group: Eurofins Genoma (Italy) is a molecular genetics and reproductive diagnostics laboratory offering NIPT, PGT, prenatal testing, and hereditary cancer panels. It is a direct peer to ATG with highly overlapping test menus (NIPT, PGT, karyotype), NGS-based workflows, and a regional reference-lab business model in Southern Europe.
• Lifecodexx: Lifecodexx is a European genetics laboratory focused on non-invasive prenatal testing (NIPT) and prenatal diagnostics, headquartered in Germany. It is directly comparable to ATG given its overlapping Panorama-equivalent NIPT franchise, prenatal genetic testing menu, and physician-led referral model across European markets.
• Genomed: Genomed is a Polish molecular diagnostics and reference laboratory offering NGS-based genetic testing, NIPT, hereditary cancer, and reproductive genetics. Comparable to ATG as a Central European competitor with similar physician-referral model and accreditation-driven differentiation strategy.
• Yourgene Health: Yourgene Health is a UK-based molecular diagnostics company focused on reproductive health, NIPT, and genetic testing using NGS technologies. It directly overlaps with ATG's prenatal/genetic test menu and Illumina-based workflows, making it a clear comparable in reproductive genetics.

Broad incumbents

• Synlab AG: Synlab is one of Europe's largest medical diagnostics networks, operating hundreds of laboratories across the continent with broad menus including genetic, prenatal, and specialty testing. It is comparable to ATG as a regional roll-up acquirer and reference lab competitor, though it is far broader and not genetics-specialized.
• Unilabs: Unilabs is a major European diagnostics chain offering routine and specialty testing, with growing genetics/NIPT service lines across multiple countries. Comparable to ATG as a broader incumbent and potential regional consolidator, though it is far larger and not genetics-specialized.
• Natera Inc. Natera is a US-based genetic testing company whose Panorama NIPT platform is licensed to and used by ATG. It is comparable as the underlying technology provider and global benchmark for NIPT quality (>98% sensitivity) and as a broader incumbent expanding into oncology and organ health.
• Cerba Healthcare: Cerba Healthcare is a European leader in clinical pathology and specialty diagnostics, including genetic and reproductive testing, operating across multiple countries. It overlaps with ATG in genetic diagnostics and serves as a broader incumbent whose specialty division competes for send-out and reference work.

Regional players

• Medicover Genetics: Medicover operates diagnostic clinics and labs across Central and Eastern Europe, including genetic testing. It is comparable to ATG as a regional, multi-country diagnostics operator with genetic services, though broader (general medicine + diagnostics) and operating primarily outside Greece/Serbia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/access-to-genome---atg

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATG - Access To Genome